Oramed Pharmaceuticals Inc. (ORMP) Institutional Ownership

Ownership Summary

Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) showed up in the 13F filings of 54 institutional investors as of December 2025.

• These investors collectively held 26.5% of Oramed Pharmaceuticals's outstanding shares in December 2025, up from 21.8% in September 2025.
• They increased total shares held in Oramed Pharmaceuticals by 21.52% from the prior quarter, while the number of investors in ORMP decreased 3.57% year over year.
• Activity in ORMP broke down as 27 buyers, 10 sellers, and 17 unchanged among 54 total holders.
• Institutional investors collectively held 11.32Mn shares in Oramed Pharmaceuticals as of December 2025, up by 2.0Mn shares quarter on quarter, and up 3.6Mn shares year over year.
• As of December 31, 2025, BML Capital Management, LLC held the largest stake in Oramed Pharmaceuticals with 3.17Mn shares, accounting for 7.4% of total shares outstanding.
• The most significant purchases of ORMP for the quarter ending December 2025 came from MERCER GLOBAL ADVISORS INC /ADV (1.91Mn), RITHOLTZ WEALTH MANAGEMENT (155.48K), Aquamarine Financial (Cayman) Ltd (139.26K), O'SHAUGHNESSY ASSET MANAGEMENT, LLC (116.36K), SUSQUEHANNA INTERNATIONAL GROUP, LLP (110.23K).
• The biggest sellers of Oramed Pharmaceuticals for the quarter ending December 2025 included Gem Investment Advisors, LLC (358.73K), Rathbones Group PLC (233.02K), CITADEL ADVISORS LLC (97.39K), JANE STREET GROUP, LLC (25.72K), Murchinson Ltd. (24.95K).
• Oramed Pharmaceuticals's 10 largest shareholders as of December 2025 include BML Capital Management, LLC (3.17Mn), Aquamarine Financial (Cayman) Ltd (2.11Mn), MERCER GLOBAL ADVISORS INC /ADV (1.91Mn), Gem Investment Advisors, LLC (1.64Mn), Murchinson Ltd. (1.32Mn), BOOTHBAY FUND MANAGEMENT, LLC (600.72K), MARSHALL WACE, LLP (259.61K), Rathbones Group PLC (233.02K), DIMENSIONAL FUND ADVISORS LP (158.21K), Wells Fargo & Company/Mn (157.59K) per Business Quant data.